newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

  • Cogent Biosciences submitted the SUMMIT NDA for bezuclastinib in NonAdvSM patients in December 2025 with FDA acceptance expected in February 2026
  • The company initiated the PEAK NDA for bezuclastinib in 2L GIST patients under Real-Time Oncology Review with completion on track for April 2026
  • The APEX NDA submission for bezuclastinib in AdvSM patients remains on track for the first half of 2026
  • Six abstracts from the SUMMIT trial were accepted for presentation at the 2026 AAAAI annual meeting
  • Bezuclastinib received Breakthrough Therapy Designation for the GIST indication based on the PEAK trial results
  • The PEAK trial demonstrated a median progression free survival of 16.5 months for bezuclastinib plus sunitinib versus 9.2 months for sunitinib monotherapy
  • The APEX trial showed an objective response rate of 57% per mIWG criteria 80% per PPR criteria, with 89% of patients achieving significant bone marrow mast cell reduction
  • Sixteen-point-five months median progression free survival was reported for the bezuclastinib combination in the PEAK trial
  • Cogent raised approximately $546.8 million from public offerings of stock and convertible notes in November 2025
  • Cash equivalents marketable securities totaled $900.8 million as of December 31 2025, providing funding runway into 2028
  • Research and development expenses were $269.8 million for the full year 2025 and $75.6 million for the fourth quarter 2025
  • General and administrative expenses were $63.6 million for the full year 2025 and $23.9 million for the fourth quarter 2025
  • The company reported a net loss of $328.9 million for the full year 2025 and $102.5 million for the fourth quarter 2025
  • Plans include launching bezuclastinib in the second half of 2026 following potential FDA approval
  • Cogent announced expanded access programs for U.S. patients with GIST or Systemic Mastocytosis
  • New pipeline updates include preclinical data for JAK2 inhibitor CGT1145 and KRAS inhibitor CGT1263/CGT1815
  • The company granted inducement equity awards to twelve new employees in February 2026